F. Ricciardolo (Orbassano, Italy), N. Roche (Paris, France), O. S. Usmani (London, United Kingdom), P. Paredi (London, United Kingdom)
Demonstration skills and knowledge for inhalers use are lacking among NCHD and nurses
O. Mikulich, L. Abdul, C. Mc Donnell, P. Ryan, B. Casserly, A. O'Brien (Limerick, Ireland)
|   |
Evaluation of inhaler devices device usage skills among the medical personnels (pulmonologist, family physician, nurse), pharmacist and assistant pharmacist
D. Gorgun, F. Yilmaz, C. G. Özkan, A. Durmaz, F. Nazik (Erzurum, Turkey)
| |
Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD
W. Azouz, P. Chetcuti, H. Hosker, D. Saralaya, H. Chrystyn (Huddersfield, Leeds, Steeton, Keighley, Bradford, United Kingdom)
| |
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV)
L. Weisfeld, G. Gopalan, Y. Shu, B. Baconnet, T. Shah (Miami, Frazer, United States Of America; Maisons Alfort, France)
| |
Inhaler competence and patient satisfaction with a DPI; results of two real-life studies in asthma and COPD
G. Gálffy, G. Mezei, G. Németh, L. Tamasi, V. Müller, O. Selroos, M. Orosz (Budapest, Miskolc, Hungary; Vejbystrand, Sweden)
| |
Comparison of the in vitro performance of originator and generic drug-combination dry powder inhalers
N. Teekamp, P. Hagedoorn, B. G. Huijbers, D. Gjaltema, H. W. Frijlink, A. H. de Boer (Groningen, Netherlands)
| |
Measures of nebulizer performance – Comparing like with like
R. Hatley, Y. Degtyareva, R. Potter (Chichester, United Kingdom)
| |
COPD: GOLD 2011 and implications for clinical practice
D. Apolinário, R. Reis, A. I. Loureiro, C. Pinto, A. Afonso (Vila Real, Portugal)
| |
Identification of COPD patient factors associated with nighttime and early morning symptoms
S. Sullivan, Q. Cai, J. Stephenson, H. Tan, A. Kavati, M. Mocarski, J. Doshi (Seattle, Wilmington, Jersey City, Philadelphia, United States Of America)
| |
Development and validation of an innovative self-administered computerized (SAC) version of baseline/transition dyspnea index (BDI/TDI) for evaluating breathlessness in patients with COPD: The BLAZE study
D. A. Mahler, V. Brunel, T. White, V. Alagappan, H. Chen, K. Kulich, N. Gallagher, D. Banerji (Hanover, East Hanover, United States Of America; Lyon, France; Basel, Switzerland; Horsham, United Kingdom)
| |
Exhaled NO but not eosinophilic inflammation is reduced by inhaled corticosteroid treatment in COPD
A. Malinovschi, G. Johansson, P. Venge, H. Hedenström, C. Janson, K. Alving (Uppsala, Sweden)
| |
The multicomponent nature of difficult asthma
B. Dyke, T. Rahman, V. Joshi, V. Patil, C. Townshend, R. Kurukulaaratchy (Southampton, Newport, United Kingdom)
| |
Association of asthma admissions and health related quality of life (HRQoL), asthma control and severity
I. Karpha, M. Murthy, R. Yadavilli, D. Lees, H. Burhan (Liverpool, United Kingdom)
| |
Medication adherence and risk of severe exacerbations in asthma- A systematic review
M. Engelkes, H. Janssens, J. de Jongste, M. Sturkenboom, K. Verhamme (Rotterdam, Netherlands)
| |
Using induced sputum cell counts to guide management of difficult-to-treat asthmatics
M. Murthy, J. Scanlan, R. Niven, S. Scott (Chester, Manchester, United Kingdom)
| |
Sub-microgram dose formulations for dose ranging studies with long acting bronchodilators and their fixed dose combination using metered dose inhalers (MDIs)
B. Noga, D. Lechuga-Ballesteros, V. Joshi, R. Schultz, J. Howland, H. Cummings, C. Orevillo, C. Reisner, S. Dwivedi (Redwood City, United States Of America)
| |
Enhanced anti-inflammatory gene expression in humans following inhaled budesonide
R. Leigh, E. King, C. Dumonceaux, C. Gwozd, S. Traves, M. Kelly, A. Miller-Larsson, R. Newton (Calgary, Canada; Mölndal, Sweden)
| |
Influence of systemic steroid treatment on bronchoalveolar (BAL) cytological composition and cell cycle in selected interstitial lung diseases
A. Dyczek, P. Kopinski, J. Chorostowska-Wynimko, K. Sladek, J. Soja, C. Rybacki, I. Patyk, A. Szpechcinski (Krakow, Bydgoszcz, Warszawa, Poland)
| |
Laninamivir’s prolonged intrapulmonary retention: Intrapulmonary pharmacokinetics (PK) and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate (LO)
H. Furuie, K. Toyama, K. Koyama, D. Nakai, H. Ishizuka (Osaka, Shinagawa-ku, Japan)
| |
Anti-human heat shock protein 60 antibodies and longitudinal change in percent emphysema and lung function: The MESA lung study
C. P. Aaron, E. A. Hoffman, R. Tracy, J. Schwartz, K. Hinckley Stukovsky, L. J. Smith, K. M. Donohue, R. G. Barr (New York, Iowa City, Colchester, Seattle, Chicago, United States Of America)
| |